Circassia Pharmaceuticals (LON:CIR) Earns Buy Rating from Peel Hunt

Circassia Pharmaceuticals (LON:CIR)‘s stock had its “buy” rating reaffirmed by analysts at Peel Hunt in a report released on Monday, ThisIsMoney.Co.Uk reports.

Several other equities analysts also recently issued reports on CIR. Peel Hunt reissued a “buy” rating and issued a GBX 70 ($0.91) target price on shares of Circassia Pharmaceuticals in a research report on Tuesday, October 15th. FinnCap initiated coverage on Circassia Pharmaceuticals in a research report on Thursday, September 26th. They issued a “corporate” rating and a GBX 80 ($1.05) target price on the stock. One investment analyst has rated the stock with a hold rating and three have given a buy rating to the stock. Circassia Pharmaceuticals currently has an average rating of “Buy” and an average price target of GBX 79 ($1.03).

Shares of CIR stock opened at GBX 16.75 ($0.22) on Monday. The business’s fifty day simple moving average is GBX 17.10 and its 200-day simple moving average is GBX 21.35. The company has a market cap of $62.84 million and a PE ratio of -0.50. The company has a current ratio of 0.40, a quick ratio of 0.35 and a debt-to-equity ratio of 21.61. Circassia Pharmaceuticals has a 12-month low of GBX 13.25 ($0.17) and a 12-month high of GBX 72.20 ($0.94).

In other news, insider Jonathan Emms bought 300,000 shares of the business’s stock in a transaction that occurred on Monday, September 30th. The shares were purchased at an average cost of GBX 17 ($0.22) per share, with a total value of £51,000 ($66,640.53).

About Circassia Pharmaceuticals

Circassia Pharmaceuticals plc, a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of respiratory diseases. The company markets NIOX and NIOX VERO for use in asthma diagnosis and management; and Tudorza for the treatment of chronic obstructive pulmonary disease (COPD).

Further Reading: Most Active Stocks

Receive News & Ratings for Circassia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Circassia Pharmaceuticals and related companies with's FREE daily email newsletter.